0000000000677598

AUTHOR

D. Centonze

showing 4 related works from this author

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving…

2011

Abstract Background Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than clinical measures; however, clinical and MRI outcomes tend to correlate poorly. Methods In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability Status Scale score ≤4.0]) receiving interferon (IFN) β-1a therapy (44 or 22 µg subcutaneously [sc] three times weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In this post hoc analysis, MRI outcomes and corre…

MalePathologyNeurologyDiseaseRelapsing-RemittingNeuropsychological Testslcsh:RC346-4290302 clinical medicineRelapsing-Remitting Multiple Sclerosi030212 general & internal medicine10. No inequalitymedicine.diagnostic_testBrainGeneral MedicineMagnetic Resonance Imaging3. Good healthFemaleSettore MED/26 - NeurologiaRadiologyNeurosurgeryMagnetic Resonance Imaging; Neuroimaging; Immunologic Factors; Dose-Response Relationship Drug; Humans; Brain; Interferon-beta; Quality of Life; Multiple Sclerosis Relapsing-Remitting; Cognition Disorders; Adult; Neuropsychological Tests; Female; MaleDrugInterferon beta-1aResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisClinical NeurologyNeuroimagingDose-Response Relationship03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingNeuroimagingmedicineImmunologic FactorsHumansNeurochemistrylcsh:Neurology. Diseases of the nervous systemDose-Response Relationship Drugbusiness.industryMultiple sclerosisMagnetic resonance imagingBrain Magnetic Resonance ImagingInterferon-betamedicine.diseaseClinical trialBrain Magnetic Resonance Imaging; Relapsing-Remitting Multiple Sclerosis; Interferon beta-1aQuality of LifeNeurology (clinical)businessCognition Disorders030217 neurology & neurosurgery
researchProduct

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting …

2010

The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for c…

Maleinterferon beta-1aKaplan-Meier EstimateRelapsing-RemittingNeuropsychological TestsCohort StudiesDisability EvaluationMedicineMale; Adolescent; Young Adult; Middle Aged; Kaplan-Meier Estimate; Cognition Disorders; Survival Analysis; Female; Disability Evaluation; Dose-Response Relationship Drug; Humans; Multiple Sclerosis Relapsing-Remitting; Prospective Studies; Cohort Studies; Disease Progression; Interferon-beta; Injections Subcutaneous; Neuropsychological Tests; Adult; Immunologic Factors; Endpoint DeterminationProspective StudiesProspective cohort studyinterferon beta multiple sclerosis cognitive impairmentSubcutaneousCognitive disorderHazard ratioMiddle AgedSettore MED/26 - NEUROLOGIANeurologyDisease ProgressionSettore MED/26 - NeurologiaFemaleDrugmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentEndpoint DeterminationInjections SubcutaneousLower riskInjectionsDose-Response RelationshipYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicineHumansImmunologic Factorscognitive functioncognitive impairmentExpanded Disability Status ScaleDose-Response Relationship Drugbusiness.industryInterferon beta-1aMcDonald criteriaOdds ratioInterferon-betamedicine.diseaseSurvival AnalysisSurgerydisabilityNeurology (clinical)businessCognition Disorderscognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
researchProduct